Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Receivables - Other (2016 - 2023)

Historic Receivables - Other for Niagen Bioscience (NAGE) over the last 11 years, with Q1 2023 value amounting to $3.5 million.

  • Niagen Bioscience's Receivables - Other rose 5217.39% to $3.5 million in Q1 2023 from the same period last year, while for Mar 2023 it was $3.5 million, marking a year-over-year increase of 5217.39%. This contributed to the annual value of $3.1 million for FY2022, which is 4761.9% up from last year.
  • Latest data reveals that Niagen Bioscience reported Receivables - Other of $3.5 million as of Q1 2023, which was up 5217.39% from $3.1 million recorded in Q4 2022.
  • In the past 5 years, Niagen Bioscience's Receivables - Other registered a high of $3.5 million during Q1 2023, and its lowest value of $800000.0 during Q4 2019.
  • For the 5-year period, Niagen Bioscience's Receivables - Other averaged around $1.9 million, with its median value being $1.9 million (2019).
  • In the last 5 years, Niagen Bioscience's Receivables - Other skyrocketed by 15265.96% in 2019 and then crashed by 4090.91% in 2022.
  • Over the past 5 years, Niagen Bioscience's Receivables - Other (Quarter) stood at $800000.0 in 2019, then grew by 12.5% to $900000.0 in 2020, then soared by 133.33% to $2.1 million in 2021, then soared by 47.62% to $3.1 million in 2022, then increased by 12.9% to $3.5 million in 2023.
  • Its Receivables - Other stands at $3.5 million for Q1 2023, versus $3.1 million for Q4 2022 and $2.4 million for Q3 2022.